Welcome to the e-CCO Library!

P481: profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Suarez Ferrer, C.J.(1);Mesonero, F.(2);Caballol, B.(3);Ballester, M.P.(4);Baston Rey, I.(5);Castaño Garcia, A.(6);MIranda Bautista, J.(7);Saiz Chumillas, R.(8);Benitez, J.M.(9);Sanchez Delgado, L.(10);Lopez-Garcia, A.(11);Rubin de Celio, C.(12);Alonso Abreu, I.(13);Melcarne, L.(14);Plaza Santos, R.(15);Marques Cami, M.(16);Caballero Mateos, A.(17);Gomez Diez, C.(18);Calafat, M.(19);Alonso Galan, H.(20);Vega Vilaamil, P.(21);Castro Sensosian, B.(22);Guerro Moya, A.(23);Rodriguez Diaz, C.Y.(24);Spicakova, K.(25);Manceñido Marcos, N.(26);Molina, G.(27);De Castro, L.(28);Rodriguez Angulo , A.(29);Cuevas del Campo , L.(30);Rodriguez Grau, M.C.(31);Ramirez, F.(32);Gomez Pastrana, B.(33);Gonzalez Partida, I.(34);Botella Mateu, B.(35);Peña Gonzalez, E.(36);Iyo, E.(37);Elosua Gonzalez , A.(38);Mañosa Ciria, M.(39);Barreiro-De Acosta, M.(40);
Created: Friday, 11 February 2022, 3:56 PM
P481: Serum levels of infliximab associate with early mucosal healing in Crohn's disease: different “therapeutic window” between post-induction and maintenance treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Feng T.1, Chen B.1, Mao R.1, Ben-Horin S.2, Chen M.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P481: Visceral fat to skeletal muscle area ratio predicts for Ustekinumab loss of response.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Tan, Z.(1)*;Chin, A.(2);Welman, C.J.(3,4);Thin, L.W.Y.(1,5);
Created: Friday, 14 July 2023, 11:05 AM
P482 Patient and physician perspectives on the management of inflammatory bowel disease: Disease remission and durability of treatment
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Afzali1, A. Armuzzi2, Y. Bouhnik3, B. Bressler4, A. Hart5, D. Rubin6, M. Sans7, B. Siegmund8, C. Sninsky9

Created: Thursday, 30 January 2020, 10:12 AM
P482: Different characteristics of inflammatory bowel disease patients between tertiary referral centres and secondary hospitals
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. H. Song*1, Y. J. Lee2, K. O. Kim3, H. S. Lee4, E. S. Kim2, J. I. Koo1, J. S. Jeong1, W. S. Seo1

Created: Friday, 22 February 2019, 9:49 AM
P482: Early anti-TNF/immunomodulator therapy is associated with better clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Oh E.H.*1, Oh K.1, Seo H.2, Chang K.2, Kim G.-U.2, Song E.M.2, Seo M.2, Lee H.-S.3, Kwon E.J.2,4, Hwang S.W.2,4, Park S.H.2,4, Yang D.-H.2, Kim K.-J.2,4, Byeon J.-S.2, Myung S.-J.2, Yang S.-K.2,4, Ye B.D.2,4

Created: Wednesday, 20 February 2019, 10:36 AM
P482: Pre-screening IBD patients starting biologic therapies, a positive single centre quality improvement project
Year: 2022
Source: ECCO'22
Authors: Colclough, J.(1);Ali, M.(2);Shami, N.(2);Aitchison, L.(2);Hurst, A.(2);Shams-Khan, H.(2);
Created: Friday, 11 February 2022, 3:56 PM
P482: Safety and efficacy of ustekinumab for Crohn’s disease in the elderly population
Year: 2021
Source: ECCO'21 Virtual
Authors: Fiske, J.(1);Liu, E.(2);Limdi, J.(2);Conley, T.E.(1);Townsend, T.(1);Davies, M.(3);Brockwell, R.(3);Baig, D.(1);Abdelbadiee, S.(1);Uney, A.(1);Liaros, A.(4);Gaba, W.(5);Smith, P.J.(1);Subramanian, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P482: Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Ye*1, M. Chen2, X. Gao3, K. Wu4, Z. Ran5, H. Yang6, Z. Liu7, Q. Cao8

Created: Friday, 22 February 2019, 9:41 AM
P482: Transanal minimally invasive proctectomy (TaMIP) in patients with inflammatory bowel diseases (IBD) within the TaTME international database
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Pellino1,2*, K. Sahnan2,3, M. Penna3,4, S. Adegbola2,3, P. Chandrasinghe2,3,5, A. Spinelli6,7, R. Hompes4, J. Warusavitarne2,3, on behalf of the International TaTME Registry Collaborative

Created: Thursday, 21 February 2019, 9:14 AM
P483 Vedolizumab serum drug levels are not associated with clinical outcomes or markers of disease activity in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Shields1, J.P. Seenan1, E. Nowell1, A. Dunlop2, P. Galloway2, J. Macdonald1

Created: Thursday, 30 January 2020, 10:12 AM
P483: Differences in biologic therapy utilisation amongst early and late-onset inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Raimundo Fernandes*, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, L. Correia, J. Velosa

Created: Friday, 22 February 2019, 9:49 AM
P483: Factors affecting the efficacy of granulomonocytapheresis in moderately-to-severely active ulcerative colitis: A multi-centre retrospective study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Yamamoto1, T. Iida2, K. Ikeya2, M. Kato2, A. Matsuura2, S. Tamura3, R. Takano3, S. Tani4, S. Osawa4, K. Sugimoto3, T. Shimoyama*1, H. Hanai2

Created: Friday, 22 February 2019, 9:41 AM
P483: Golimumab response in Ulcerative Colitis as early as week 2: What can we take from this?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kumar, L.(1)*;O'Morain, N.(1);Sheridan, J.(1);Coe, C.(1);Egan, C.(1);Jones, F.(1);Cullen, G.(1);Doran, P.(2);Leyden, J.(3);Galligan, M.(2);McCarthy, J.(4);O'Toole, A.(5);Kevans, D.(6);Egan, L.(7);Doherty, G.(1);
Created: Friday, 14 July 2023, 11:05 AM
P483: Infliximab but not adalimumab drug levels predict faecal calprotectin response in Inflammatory Bowel Disease patients on dose-intensified anti-TNF therapy
Year: 2021
Source: ECCO'21 Virtual
Authors: Noack, S.(1);Little, R.(1);Vaz, K.(1);Ward, M.(1);Sparrow, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P483: Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Explorative subgroup analyses in IBD from the NOR-SWITCH EXTENSION trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

K.K. Jørgensen1*, G.L. Goll2, J. Sexton2, I.C. Olsen2,3, N. Bolstad4, K.E. Lundin5,6, I.P. Berset7, E.A. Haavardsholm2,6, C. Mørk8, T.K. Kvien2,6, J. Jahnsen1,6

Created: Thursday, 21 February 2019, 9:14 AM
P483: Patient-reported quality of life, anxiety, and depression associated with switching originator infliximab to biosimilar
Year: 2022
Source: ECCO'22
Authors: Ritter, T.E.(1);Mehta, S.A.(2);Van Anglen, L.J.(2);
Created: Friday, 11 February 2022, 3:56 PM
P483: Relapse after discontinuation of the maintenance drug in patients with Ulcerative proctosigmoiditis: preliminary result of a prospective randomized trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Choi H.*1, Gweon T.-G.2, Lee B.-I.2, Lee K.-M.2, Kim S.-W.2, Kang S.-B.2, Ji J.-S.2, Han S.-W.2, Choi M.-G.2

Created: Wednesday, 20 February 2019, 10:36 AM
P484 Effectiveness and safety of ustekinumab in patients with Crohn’s disease: a real-world experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Mohammad1, A. Alshahrani1,2, Y. Bao1, R. Alramdan1, A. Rajani1, U. Chauhan1, B. Salena1, F. Tse1, E. Greenwald1, S. Albashir1, S. Halder1, D. Armstrong1, J. Marshall1, N. Narula1

Created: Thursday, 30 January 2020, 10:12 AM